An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)
This study is ongoing, but not recruiting participants.
First Posted: April 21, 2014
Last Update Posted: April 20, 2017
Lumena Pharmaceuticals, Inc.
Childhood Liver Disease Research and Education Network
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||October 19, 2018|
|Estimated Primary Completion Date:||October 19, 2018 (Final data collection date for primary outcome measure)|